|
Symposium
[Free Online] Oncology Business Development and Partnering: perspectives and advice from buyers
Speakers:
Lizabeth Leveille, Merck; Lesley Stolz, JNJ
Organizers:
Sarah Bodary, PhD; Jeff McMahon, PhD; Jimmy Zhang, PhD
Date:
2024-03-15
Time:
8:30-11:30 Pacific Time
Registration fee:
0
Location:
Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2024-03-14
(it will close sooner if the seating cap is reached)
About the Topic
The symposium is intended to bring together BD leaders from pharma and venture with private biotechs focusing on oncology. The forum will provide "buyers" the opportunity to share their wish lists and advice on what is of interest from a Search and Evaluation perspective through brief presentations. Biotech participants will have an opportunity to pose questions to specific panel members after the presentations and in a panel discussion.
| Time (PT) |
Time (ET) |
Speaker |
| 8:30-8:40 AM |
11:30-11:40 AM |
Shichang Miao, PhD, PBSS |
| 8:40-8:45 AM |
11:40-11:45 AM |
Sarah Bodary, PhD, Darwin Bodary Consulting |
| 8:45-9:10 AM |
11:45 AM-12:10 PM |
Lizabeth Leveille, PhD, Vice President, Merck & Co |
| 9:10-9:35 AM |
12:10-12:35 PM |
Lesley Stolz, PhD, Vice President, Johnson & Johnson |
| 9:35-10:15 AM |
12:35-1:15 PM |
Panel Discussion and Wrap-up |
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: Untangling What We Thought We Knew and Future Precision Diagnostics and Therapeutics
|
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro Delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad
($250 for 2 months)
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Lena Biosciences
Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Submit a Text Ad
|